Earnings History Data for OncoCyte Corporation (OCX) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
OncoCyte Corporation
OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.
Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
08-08-2024 | AH | OCX | OncoCyte Corporation | 40.76 | -0.36 | 0.00 | -1.07 | OncoCyte GAAP EPS of -$0.36 beats by $0.19, revenue of $0.1M misses by $0.21M [8/8/2024 4:27 PM] |
3.12 | 0.04 (1.30%) |
0.0 | 0.0 (0.00%) |
2.08 - 4.34 | 38,770 | 20,000 | 0 | ||
15-05-2024 | AH | OCX | OncoCyte Corporation | 23.91 | -1.13 | -0.82 | -0.80 | OncoCyte GAAP EPS of -$1.13 misses by $0.46, revenue of $0.18M misses by $0.17M [5/15/2024 4:27 PM] |
3.07 | 0.12 (4.07%) |
2.75 | -0.20 (-6.78%) |
2.08 - 5.40 | 63,591 | 20,000 | 41,173 | ||
09-11-2023 | PM | OCX | OncoCyte Corporation | 19.20 | -0.57 | -1.52 | -1.60 | OncoCyte GAAP EPS of -$0.81 beats by $0.20, revenue of $0.43M beats by $0.12M [11/9/2023 7:27 AM] |
2.70 | 0.62 (29.81%) |
2.51 | 0.43 (20.67%) |
2.08 - 13.20 | 83,861 | 20,000 | 9,510 | ||
10-08-2023 | PM | OCX | OncoCyte Corporation | 29.50 | -1.07 | -2.60 | -1.40 | OncoCyte GAAP EPS of -$1.03 beats by $0.21, revenue of $0.46M beats by $0.11M [8/10/2023 7:05 AM] |
3.50 | -0.01 (-0.28%) |
0.0 | 0.0 (0.00%) |
3.48 - 22.00 | 16,522 | 40,000 | 0 | ||
11-05-2023 | PM | Before the open (May 11) |
OCX | OncoCyte Corporation | 32.78 | -0.04 | -0.12 | -0.11 | OncoCyte GAAP EPS of $0.04 beats by $0.13, revenue of $0.3M misses by $0.04M [5/11/2023 8:06 AM] |
0.2788 | 0.01 (4.50%) |
0.0 | 0.0 (0.00%) |
0.20 - 1.35 | 84,997 | 190,000 | 0 | |
03-04-2023 | PM | OCX | OncoCyte Corporation | 47.46 | N/A | 0.00 | -0.12 | OncoCyte reports Q4 results [4/3/2023 1:06 AM] |
0.3176 | -0.04 (-10.38%) |
0.32 | -0.03 (-9.71%) |
0.20 - 1.60 | 440,660 | 500,000 | 28,954 | ||
10-11-2022 | AH | 4:05 PM ET (Nov 10) |
OCX | OncoCyte Corporation | 74.94 | -0.08 | -0.13 | -0.13 | OncoCyte GAAP EPS of -$0.08 beats by $0.03, revenue of $1M misses by $0.48M [11/10/2022 4:36 PM] |
0.4748 | -0.13 (-20.92%) |
0.65 | 0.05 (8.26%) |
0.45 - 3.56 | 1,599,172 | 420,000 | 3,083 | |
10-08-2022 | AH | 4:05 PM ET (Aug 10) |
OCX | OncoCyte Corporation | 101.25 | -0.07 | -0.13 | -0.11 | OncoCyte GAAP EPS of -$0.07 beats by $0.05, revenue of $2.1M misses by $0.66M [8/10/2022 4:20 PM] |
0.9945 | 0.04 (4.59%) |
0.90 | -0.05 (-5.35%) |
0.81 - 5.48 | 182,918 | 220,000 | 150 | |
11-05-2022 | AH | 4:05 PM ET (May 11) |
OCX | OncoCyte Corporation | 130.36 | -0.11 | -0.13 | -0.04 | OncoCyte GAAP EPS of -$0.11 beats by $0.01, revenue of $1.43M misses by $0.81M [5/11/2022 4:12 PM] |
1.09 | -0.04 (-3.10%) |
1.09 | -0.04 (-3.54%) |
1.09 - 6.25 | 607,972 | 550,000 | 3,146 | |
10-03-2022 | AH | 4:05 PM ET (Mar 10) |
OCX | OncoCyte Corporation | 115.29 | -0.12 | -0.09 | -0.09 | OncoCyte GAAP EPS of -$0.39 misses by $0.26, revenue of $3.5M misses by $0.02M [3/10/2022 4:19 PM] |
1.28 | -0.11 (-8.21%) |
1.48 | 0.08 (5.71%) |
1.22 - 6.25 | 268,893 | 250,000 | 2,112 | |
09-11-2021 | AH | 4:00 PM ET (Nov 9) |
OCX | OncoCyte Corporation | 316.82 | -0.13 | -0.07 | -0.10 | OncoCyte EPS misses by $0.03, misses on revenue [11/9/2021 4:10 PM] |
3.33 | -0.25 (-6.98%) |
3.39 | -0.19 (-5.31%) |
1.56 - 6.57 | 259,702 | 300,000 | 1,339 | |
10-08-2021 | AH | 4:00 PM ET (Aug 10) |
OCX | OncoCyte Corporation | 473.76 | -0.11 | -0.08 | -0.14 | OncoCyte EPS misses by $0.02, beats on revenue [8/10/2021 4:16 PM] |
4.07 | -0.93 (-18.63%) |
4.87 | -0.13 (-2.60%) |
1.15 - 6.57 | 1,867,517 | 320,000 | 785 | |
17-05-2021 | AH | 4:00 PM ET (May 17) |
OCX | OncoCyte Corporation | 383.08 | -0.04 | -0.09 | -0.13 | OncoCyte EPS beats by $0.05, beats on revenue [5/17/2021 4:01 PM] |
4.31 | 0.25 (6.16%) |
4.05 | -0.01 (-0.25%) |
1.15 - 6.57 | 499,708 | 470,000 | 1,589 | |
16-03-2021 | AH | 4:05 PM ET (Mar 16) |
OCX | OncoCyte Corporation | 425.24 | -0.09 | -0.10 | -0.15 | OncoCyte EPS beats by $0.02, misses on revenue [3/16/2021 4:06 PM] |
4.92 | -0.21 (-4.09%) |
5.16 | 0.03 (0.58%) |
1.15 - 6.57 | 1,218,510 | 1,208,326 | 24,503 | |
|
||||||||||||||||||
12-11-2020 | AH | 4:05 PM ET (Nov 12) |
OCX | OncoCyte Corporation | 114.33 | -0.10 | -0.09 | -0.10 | OncoCyte EPS in-line, beats on revenue [11/12/2020 4:19 PM] |
1.76 | 0.08 (4.76%) |
1.68 | 0.0 (0.00%) |
1.15 - 3.51 | 643,088 | 358,711 | 3,450 | |
|
||||||||||||||||||
29-07-2020 | AH | 4:05 PM ET (Jul 29) |
OCX | OncoCyte Corporation | 92.76 | -0.14 | -0.11 | -0.10 | OncoCyte EPS misses by $0.04, beats on revenue [7/29/2020 4:17 PM] |
1.40 | 0.02 (1.82%) |
1.32 | -0.05 (-3.65%) |
1.20 - 3.51 | 421,372 | 765,696 | 6,755 | |
|
||||||||||||||||||
12-05-2020 | AH | 4:05 PM ET (May 12) |
OCX | OncoCyte Corporation | 188.88 | -0.13 | -0.11 | -0.08 | OncoCyte EPS misses by $0.02 [5/12/2020 4:10 PM] |
2.87 | 0.17 (6.30%) |
2.80 | -0.07 (-2.44%) |
1.50 - 5.60 | 601,830 | 556,708 | 9,402 | |
|